cancer

Did AstraZeneca fake clinical trial data for its ovarian cancer drug?


Most Viewed Articles
Popular on Facebook
The five biggest lies about Ebola being pushed by government and mass media
Why does the CDC own a patent on Ebola 'invention?'
White House admits staging fake vaccination operation to gather DNA from the public
Ultraviolet light robot kills Ebola in two minutes; why doesn't every hospital have one of these?
EXCLUSIVE: Natural News tests flu vaccine for heavy metals, finds 25,000 times higher mercury level than EPA limit for water
Truvia sweetener a powerful pesticide; scientists shocked as fruit flies die in less than a week from eating GMO-derived erythritol
Irrefutable proof we are all being sprayed with poison: 571 tons of toxic lead 'chemtrailed' into America's skies every year
Tetanus vaccines found spiked with sterilization chemical to carry out race-based genocide against Africans
Russia taking McDonald's to court, threatens countrywide shutdown
Oregon man serving prison sentence for collecting rainwater on his own property
The best way to help your body protect itself against Ebola (or any virus or bacteria)
Global warming data FAKED by government to fit climate change fictions
Senator who attacked Doctor Oz over dietary supplements received over $146,000 in campaign contributions from Big Pharma mega-retailer and Monsanto
Healthy 12-year-old girl dies shortly after receiving HPV vaccine
Ebola outbreak may already be uncontrollable; Monsanto invests in Ebola treatment drug company as pandemic spreads
HOAX confirmed: Michelle Obama 'GMOs for children' campaign a parody of modern agricultural politics
Ben & Jerry's switches to non-GMO, Fair Trade ice cream ingredients
W.H.O. contradicts CDC, admits Ebola can spread via coughing, sneezing and by touching contaminated surfaces

Delicious
(NaturalNews) AstraZeneca has come out making bold claims about their new experimental ovarian cancer drug called olaparib. In clinical trials, the drug company shows that their new drug enables an 83 percent reduction in the risk of ovarian cancer progression.

According to a review by officials from the US Food and Drug Administration, this 83 percent statistic most likely couldn't be reproduced.

"AstraZeneca has put up some pretty lofty expectations," said Damien Conover, an analyst at Morningstar.

The drug is designed to be a maintenance therapy for recurring ovarian cancer that has only partially responded to platinum-based chemotherapy. Could the drug's efficacy rate even be proven since it's used as a secondary, follow-up drug to chemotherapy? How can the success of these two therapies be differentiated?

For that matter, how can the efficacy of the platinum-based chemotherapy and/or the new drug be measured if it's the person's immune system that is overcoming the cancer? Drug companies can't market patients' own immune systems.

In the end, could it be that the two treatment methods are actually diverting energy away from immune system empowerment and cellular energy production?

Meanwhile, olaparib awaits FDA approval. The future of this multi-billion-dollar cash cow hinges on the decision of FDA staff. An FDA staff report, recently published on the agency's website, is preparing discussion with outside experts who will weigh the benefits versus the risks of the new drug. The FDA's decision usually hinges on the advice of these expert panels. If it is approved, olaparib is already set to be sold under the brand name Lynparza.

Clinical tests are vague, making general correlations that cannot be proven

The new drug intervenes in the body by blocking poly(ADP-ribose) polymerase (PARP) activity. This enzyme plays an important role in cell repair.

According to the clinical trials, ovarian cancer patients witnessed median improvement of seven months for progression-free survival. This test basically just measures the amount of time a patient lives without the cancer showing any signs of progression. The test does not show whether the drug is mitigating the cancer progression but does show a general correlation (that cannot be effectively proven or consistently replicated).

Measuring quality-of-life factors like energy levels and strength recovery are not included in this clinical test either. Likewise, the drug's ability to prevent other health problems and future cancers is not included in the test. To make matters worse, olaparib boasts a new set of side effects for the body to handle along with the cancer -- nausea, fatigue, abdominal pain, vomiting, diarrhea and anemia.

Drug has potential to mislead women into taking it as a "preventive" measure

The drug was designed for women who test positive for BRCA gene mutations. There are about 2,000 of these cases every year in the United States. Under this premise, pharmaceutical advertisement may lure doctors and scare patients into "preventing" ovarian cancer in women who test positive for BRCA gene mutation predisposition. If they have these genes, then they may be coerced or scared into lifetime "preventive" doses of the new ovarian cancer drug. The drug could be marketed according to its clinical trials that show an 83 percent reduction in the risk of disease progression. The method of marketing might sell over quite well, victimizing those who don't question authority, fooling women into using pills for cancer prevention.

FDA questions "the reliability of the estimation of treatment effect"

What the FDA is concerned about is how AstraZeneca conducted its data analysis. The FDA review said there is some uncertainty about the validity of the results, showing how AstraZeneca collected some of the data using archived blood samples. The FDA review formally questioned "the reliability of the estimation of treatment effect."

The review went on to say that the data suggests that most patients may experience some progression-free survival, but that benefit came from a control arm that performed unusually poorly. The review said that there was no difference between the two treatment arms and their overall survival rate.

Sources for this article include:

http://www.reuters.com

http://science.naturalnews.com

Join over four million monthly readers. Your privacy is protected. Unsubscribe at any time.
comments powered by Disqus
Take Action: Support NaturalNews.com by linking back to this article from your website

Permalink to this article:

Embed article link: (copy HTML code below):

Reprinting this article:
Non-commercial use OK, cite NaturalNews.com with clickable link.

Follow Natural News on Facebook, Twitter, Google Plus, and Pinterest

Colloidal Silver

Advertise with NaturalNews...

Support NaturalNews Sponsors:

Advertise with NaturalNews...

GET SHOW DETAILS
+ a FREE GIFT

Sign up for the FREE Natural News Email Newsletter

Receive breaking news on GMOs, vaccines, fluoride, radiation protection, natural cures, food safety alerts and interviews with the world's top experts on natural health and more.

Join over 7 million monthly readers of NaturalNews.com, the internet's No. 1 natural health news site. (Source: Alexa.com)

Your email address *

Please enter the code you see above*

No Thanks

Already have it and love it!

Natural News supports and helps fund these organizations:

* Required. Once you click submit, we will send you an email asking you to confirm your free registration. Your privacy is assured and your information is kept confidential. You may unsubscribe at anytime.